Salvage Chemotherapy

DRUG5 trials

Conditions

AMLAcute Myeloid Leukemia (AML)Acute Myeloid Leukemia With FLT3/ITD MutationClassical Hodgkin LymphomaFallopian Tube CarcinomaOvarian Epithelial Cancer RecurrentPrimary Peritoneal Carcinoma

Phase 3

Surgery or Chemotherapy in Recurrent Ovarian Cancer (SOC 1 Trial)?

NCT01611766

Shanghai Gynecologic Oncology GroupFallopian Tube Carcinoma, Ovarian Epithelial Cancer Recurrent, Primary Peritoneal Carcinoma

Start: 2012-07-19End: 2022-12-31Target: 356Updated: 2021-06-10

(QuANTUM-R): An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects Who Are FLT3-ITD Positive

CompletedNCT02039726

Daiichi SankyoAML

Start: 2014-05-31End: 2020-09-08Updated: 2021-02-24

Tislelizumab Monotherapy Versus Salvage Chemotherapy for Relapsed/Refractory Classical Hodgkin Lymphoma

TerminatedNCT04486391

BeiGeneClassical Hodgkin Lymphoma

Start: 2020-12-14End: 2025-10-13Updated: 2026-03-02

A Study of SKLB1028 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory (R/R) AML With FLT3-Mutated

NCT04716114

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Acute Myeloid Leukemia (AML)

Start: 2021-03-24End: 2025-12-31Target: 315Updated: 2021-11-02

A Study of XY0206 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory AML With FLT3-ITD-Mutation (ALIVE)

Not yet recruitingNCT05876832

Shijiazhuang Yiling Pharmaceutical Co. LtdAcute Myeloid Leukemia With FLT3/ITD Mutation

Start: 2023-06-15End: 2027-07-01Target: 312Updated: 2023-05-26

2024-06-0117 citations

Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): A final overall survival analysis of a multicenter, open-label, randomized, phase 3 trial.

Journal of Clinical Oncology2024-06-012 citations

Tislelizumab for Relapsed/Refractory Classical Hodgkin Lymphoma: 3-Year Follow-up and Correlative Biomarker Analysis

Clinical Cancer Research2021-10-2944 citations

Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial.

2021-03-08140 citations

Concentration–QTc analysis of quizartinib in patients with relapsed/refractory acute myeloid leukemia

Cancer Chemotherapy and Pharmacology2021-01-0815 citations

Clinical Outcomes and Characteristics of Patients (pts) with FLT3–Internal Tandem Duplication (FLT3-ITD)–Mutated Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) Undergoing Hematopoietic Stem Cell Transplant (HSCT) after Quizartinib (Q) or Salvage Chemotherapy (SC) in the Quantum-R Trial

Biology of Blood and Marrow Transplantation2020-01-233 citations

A phase II trial of cytoreductive surgery combined with niraparib maintenance in platinum-sensitive, secondary recurrent ovarian cancer: SGOG SOC-3 study

Journal of Gynecologic Oncology2020-01-0110 citations

Clinical Outcomes and Characteristics of Patients (pts) with FLT3-Internal Tandem Duplication (FLT3-ITD)-Mutated Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) Undergoing Hematopoietic Stem Cell Transplant (HSCT) after Quizartinib (Q) or Salvage Chemotherapy (SC) in the Quantum-R Trial

Blood2019-11-136 citations

Pooled Safety Analysis of Quizartinib Monotherapy in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Blood2019-11-133 citations

Effect of Co-Mutations and FLT3-ITD Variant Allele Frequency (VAF) on Response to Quizartinib or Salvage Chemotherapy (SC) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Blood2019-11-133 citations

Quality-Adjusted Time without Symptoms or Toxicity (Q-TWiST) Analysis of Quizartinib Vs Salvage Chemotherapy in Patients with Relapsed/Refractory (R/R) FLT3-ITD Acute Myeloid Leukemia (AML)

Blood2019-11-132 citations

Characterization of Response and Transfusion Independence in Patients with FLT3-Internal Tandem Duplication (FLT3-ITD)-Mutated Relapsed/Refractory Acute Myeloid Leukemia Treated with Quizartinib or Salvage Chemotherapy in the Quantum-R Trial

Blood2019-11-131 citations

A Phase 1 Study of Milademetan in Combination with Quizartinib in Patients with Newly Diagnosed (ND) or Relapsed/Refractory (R/R) FLT3-ITD Acute Myeloid Leukemia (AML)

Blood2019-11-131 citations

Exposure-Response of Quizartinib Efficacy in Patients with Relapsed/Refractory AML

Blood2019-11-13

Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial.

2019-06-04363 citations

Efficacy and Safety of Single-Agent Quizartinib (Q), a Potent and Selective FLT3 Inhibitor (FLT3i), in Patients (pts) with FLT3-Internal Tandem Duplication (FLT3-ITD)-Mutated Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) Enrolled in the Global, Phase 3, Randomized Controlled Quantum-R Trial

Blood2018-11-2936 citations

Targeted Chemotherapy vs. Immuno-Based Therapies in AML

Oncology Times2018-11-14

Safety and tolerability of quizartinib, a FLT3 inhibitor, in advanced solid tumors: a phase 1 dose-escalation trial.

2018-08-069 citations

Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial.

2018-05-31202 citations

Phase 1 study of quizartinib in combination with induction and consolidation chemotherapy in patients with newly diagnosed acute myeloid leukemia

American Journal of Hematology2017-11-1592 citations

1 more papers not shown

Salvage Chemotherapy

Sponsors

Conditions

Phase 3

Related Papers